

March 31, 2003

Terumo Corporation

Representative: Takashi Wachi, President

(Code No. 4543, Tokyo Stock Exchange First Section)

Inquiries: Kunio Kimishima, Manager, Corporate Communication Dept.

(Tel: 03-3374-8306)

To whom it may concern

Re: Revision of Forecast of Performance for the Current Fiscal Year

We would like to inform you that we have revised the forecast for the Fiscal Year ended March 31 (April 1, 2002 to March 31, 2003) as follows based on the determination of the closing account method of transactions regarding acquisitions and tie-ups, which was pending in the forecast of performance on a consolidated basis at the time of announcing the interim closing of accounts, as well as the recent trends in our business and other factors.

1. Revised Forecast of Performance on a Consolidated Basis (April 1, 2002 to March 31, 2003)

(Unit: million yen)

	Sales	Operating Income	Net Income
Previously announced forecast (A)	195,000	27,000	21,000
Revised forecast (B)	200,200	29,200	17,500
Variance (B - A)	5,200	2,200	- 3,500
Variance ratio (%)	2.7	8.1	- 16.7
(Reference) Results for the preceding period (ended March 31, 2002)	187,082	30,021	14,441
Revised forecast of year-on-year growth rate (%)	7.0	- 2.7	21.2

(Reference: Forecast of Performance on a Nonconsolidated Basis)

(Unit: million yen)

	Sales	Operating Income	Net Income
Previously announced forecast (A)	150,500	25,000	18,500
Revised forecast (B)	154,000	25,000	17,300
Variance (B - A)	3,500	0	- 1,200
Variance ratio (%)	2.3	0	- 6.5
(Reference) Results for the preceding period (ended March 31, 2002)	149,047	28,654	13,148

2. Reasons for Revision

In view of the following principal factors, upward revisions were made to sales and operating income and a downward revision was made to net income.

1) Regarding the consolidated adjustment account (approx. 19 billion yen in total) derived from the acquisition of Vascutek Ltd. in the United Kingdom last November, whereas we provisionally treated the total amount as being amortized in equal installments over 20 years in the previously announced forecast, we have now decided to adopt the following method:

- Consolidated adjustment account derived from development of state-of-the-art medical equipment:

A lump sum (approx. 3.5 billion yen) is to be amortized as an extraordinary loss in the current term.

- Remaining amount: To be amortized in equal installments over 20 years (approx. 800 million yen per year).

2) Regarding development investment in Mission Medical Inc. (approx. 1 billion yen) in the United States, which we provisionally treated as sales and general administrative expenses, we have decided to include the total amount in investment securities according to U.S. accounting practice.

3) Since sales of products in the hospital and cardiovascular business sectors are on an upward trend, we made a revision taking the impact of this on sales and profit into account.

(Reference: Forecast of Performance on a Consolidated Basis for the Term Ending March 31, 2003)

(Unit: 100 million yen)

	Previous forecast	Current forecast	Variance	Main factors for variance
Sales	1,950	2,002	52	Increase of sales in hospital and cardiovascular business sectors
Japan	1,230	1,262	32	
Overseas	720	740	20	
Gross profit (%)	945 (48.5%)	980 (49.0%)	35	
Operating income (%)	285 (14.6%)	310 (15.5%)	25	Development investment in Mission Medical Inc. (+10)
Ordinary income (%)	270 (13.8%)	292 (14.6%)	22	
Extra-ordinary P/L	79	33	-46	<ul style="list-style-type: none"> · Bulk amortization in consolidated adjustment account of Vascutek Ltd. (-35) · Appraisal of investment securities (-10)
Net income (%)	210 (10.8%)	175 (8.7%)	-35	

Exchange rates applied (averages for the term)		
US\$	123.00	122.00
E U R	117.50	119.00